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Objective: Percutaneous intervention for symptomatic renal artery atherosclerosis is rapidly replacing surgery in many
centers. This study evaluated the anatomic and functional outcomes of endovascular therapy for atherosclerotic renal
artery stenosis on a combined vascular surgery and interventional radiology service at an academic medical center.
Methods: This was a retrospective analysis of patients who underwent renal artery angioplasty with or without stenting
between January 1990 and June 2002. Indications included hypertension (86%) and rising serum creatinine concentra-
tion (55%). One hundred forty-six patients (80 women; average age, 71 years [range, 44-89 years]) underwent 183
attempted interventions (64 to treat bilateral stenosis). Forty-five percent of patients had significant bilateral disease: 27%
had greater than 50% bilateral stenosis, and the remainder had nonfunctioning, absent, or occluded vessels.
Results: Of 183 planned interventions, technical success (<30% residual stenosis) was achieved in 179 vessels (98%) with
placement of 137 stents (75%). Thirty-day mortality was 0.7%. The major morbidity rate was 4%, and the procedure-
related complication rate was 18%. Five-year cumulative patient mortality was 25%. Primary patency, assisted primary
patency, and recurrent stenosis rates were 82% 9%, 100% 0%, and 30% 7%, respectively, at 5 years. Within 3 months
of the procedure, 52% of patients who received treatment of hypertension demonstrated clinical benefit (hypertension
improved or cured), which was maintained in 68% of patients at 5 years. Serum creatinine concentration was lowered or
stabilized in 87% of patients within 3 months of the procedure, but this benefit, including freedom from dialysis, was
maintained in only 45% of patients at 5 years.
Conclusions: Endovascular intervention for symptomatic atherosclerotic renal artery stenosis is technically successful.
There were excellent patency and low recurrent stenosis rates. There is immediate clinical benefit for most patients, but
divergent long-term functional outcomes. Endovascular interventions modestly enhance the care of the patient with
hypertension, but poorly preserve long-term renal function in the patient with chronic renal impairment. (J Vasc Surg
2004;39:565-74.)Atherosclerotic renal artery stenosis is a significant
cause of poorly controlled hypertension and progressive
renal dysfunction, leading to ischemic nephropathy and
other end organ damage.1 Renal artery stenosis progresses
in 51% of renal arteries within 5 years of diagnosis.2 As
many as 5% of renal arteries with greater than 60% stenosis
per year will eventually occlude, with resultant renal atro-
phy.3 Recently the attention paid to renal artery disease has
intensified with the greater use and availability of catheter-
based interventions.
Historically, surgical revascularization was the accepted
standard of therapy, but was limited by relatively high
procedural morbidity and mortality.4 Catheter-based treat-
ment is an attractive alternative to surgical revasculariza-
tion, because it is tolerated by a greater proportion of
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doi:10.1016/j.jvs.2003.09.024affected patients. Recent studies have shown the immediate
and long-term technical success of the procedure.5-8 How-
ever, the optimal treatment of renovascular disease contrib-
uting to hypertension and renal dysfunction is not known.
Furthermore, the long-term functional outcomes of en-
doluminal therapy on hypertension and renal preservation
remain controversial.6,9,10 This study reports the anatomic
and functional outcomes of endovascular therapy for ath-
erosclerotic renal artery stenosis in a clinically and demo-
graphically mixed patient population on a combined vascu-
lar surgery and interventional radiology service at an
academic medical center.
METHODS
Experimental design and setting. We performed a
retrospective review of inpatient and office records for
patients who underwent primary renal artery angioplasty or
stenting to treat atherosclerotic renal artery disease at the
University of Rochester Medical Center between January
1990 and June 2002. For each patient, demographic data,
existing comorbid conditions, and risk factors for athero-
sclerosis were identified. Median patient follow-up was 1.3
years (average, 2.1 2.3 years; range, 0-10 years). Eighty-
nine percent of patients underwent duplex ultrasound scan-
ning at last follow-up. Last average follow-up was 1.8 2.0
years (range, 0-10 years).565
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evated serum creatinine concentration, congestive heart
failure, or diminishing renal mass underwent a diagnostic
study to identify the presence of renal artery stenosis. This
study consisted of standard angiography, magnetic reso-
nance angiography, renal isotope scanning, or duplex ultra-
sound scanning. Duplex ultrasound scanning criteria used
to identify renal artery stenosis have been described.3 In the
presence of clinical criteria defined by Rundback et al11 and
stenosis of 60% or greater on ultrasound scanning or mag-
netic resonance angiography, or a positive renal scan, an-
giography was performed. Interventions were performed in
patients with renal artery stenosis 50% or greater at angiog-
raphy, regardless of comorbid conditions. Patients who did
not meet the clinical criteria referenced were managed
medically. Nonfunctioning kidneys were not treated. In the
presence of bilateral disease, the clinical criteria for treat-
ment of both kidneys were the same as those for solitary
renal artery stenosis. Patients were followed up at 6-month
intervals after the procedure. Blood pressure,11 serum cre-
atinine concentration, and number of antihypertensive
medications were identified at these follow-up intervals. By
following the methods by Rundback et al,11 reliability of
blood pressure was ensured and observer bias was elimi-
nated. Duplex ultrasound scanning was performed in our
vascular laboratory, which is registered by the Intersocietal
Commission for Accredication of Vascular Laboratories.
Each patient underwent duplex ultrasound scanning at
least once within 6 months of the procedure, and most
underwent ultrasound at last follow-up to assess patency. If
the duplex ultrasound scan showed stenosis of 60% or
greater and the patient had recurrent symptoms, angiogra-
phy was performed and recurrent stenosis was treated if
50% or greater.
Definitions. Hypertension was defined as systolic
blood pressure greater than 140 mm Hg or diastolic blood
pressure greater than 90 mmHg on three occasions over 6
months. An elevated creatinine concentration was defined
as 1.5 mg/dL or greater on two consecutive measurements
over 3 months. Chronic renal insufficiency was defined as
serum creatinine concentration persistently greater than
1.5 mg/dL for more than 6 months. The baseline serum
creatinine concentration was the value recorded closest to
the procedure. Patients were considered to have a “non-
functioning kidney” if any two of the following local crite-
ria used at our institution over the time of the study were
met: (1) a duplex ultrasound scan demonstrated a pole-to-
pole length of less than 9 cm, with no renal flow in the main
renal artery and parenchymal peak systolic velocity less than
10 cm/s; (2) surgically or congenitally absent kidney; (3)
no visible nephrogram at contrast material–enhanced arte-
riography. Ostial lesions were defined as lesions within 1 cm
of the renal artery orifice. The procedure was considered a
success if residual stenosis was less than 30%, and a failure if
residual stenosis was 30% or greater, according to angio-
graphic measurement, including lesions that could not be
dilated or crossed. Death within 30 days of the procedure
was considered procedure-related. Primary patency wasdefined as absence of occlusion or interventions to treat
recurrent stenosis of the vessel after the primary interven-
tion. Assisted primary patency was defined as absence of
occlusion of the vessel after the primary intervention, but
including any interventions to treat recurrent stenosis. Pri-
mary recurrent stenosis was defined as a treated segment
with a duplex classification of stenosis 60% or greater.
Secondary recurrent stenosis was defined as a treated seg-
ment with a duplex classification of stenosis 60% or greater
after additional percutaneous interventions.12 Response in
patients with hypertension was defined as follows11:
“cured” hypertension was normotension, that is, diastolic
blood pressure less than 90 mm Hg and systolic blood
pressure less than 140 mm Hg, without medications; “im-
proved” hypertension was normotension, that is, diastolic
blood pressure less than 90 mm Hg and/or systolic blood
pressure less than 140 mm Hg, with the same or fewer
medications, or diastolic blood pressure 15 mm Hg below
baseline with the same or fewer medications; “no effect”
was no change or inability to meet these criteria for cure or
improvement of hypertension, and was considered a treat-
ment failure. Recurrence of hypertension was defined as
recurrence of diastolic blood pressure greater than 90 mm
Hg or systolic blood pressure greater than 140 mm Hg or
a greater than 20% increase in post-procedure baseline
diastolic blood pressure that was not treatable with repeat
angioplasty. Early and late renal function responses to
angioplasty were defined as follows: “cured” renal function
required a serum creatinine concentration less than 1.5
mg/dL; “improvement” in renal function required a
greater than 20% reduction in the serum creatinine concen-
tration; “deterioration” in renal function was considered a
treatment failure, and required a greater than 20% increase
in the serum creatinine concentration, institution of dialy-
sis, or renal related mortality.12 Patients who had a 20% or
less change in serum creatinine concentration after the
procedure were considered to have “stable” renal function.
Statistical analysis. We performed our analysis on an
“intention to treat” basis. Measured values are reported as
percentage or mean  1 SD. Survival, cumulative primary
patency, primary assisted patency, recurrent stenosis, and
clinical benefit rates were calculated with life table analysis,
and are reported with American Association for Vascular
Surgery/Society for Vascular Surgery criteria. Standard
errors are reported in life table analyses. The log-rank test
was used to determine differences between life tables. Anal-
yses were performed with SAS software (version 8.2; SAS
Institute, Cary NC). Multivariate stepwise regression anal-
ysis was used to determine the influence of preprocedural
and periprocedural factors on outcomes. The significance
level P  .10 was used to include or eliminate a covariate
from the model. Covariates were considered significantly
associated with the outcome if they were included in the
final model and their significance level was P  .05. Inter-
actions between statistically significant covariates were
checked. The Cox proportional hazards model was used for
time-dependent outcomes (mortality, recurrent stenosis,
long-term freedom from worsening hypertension, long-
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 3 Sivamurthy et al 567term freedom from renal related morbidity and mortality).
The proportional hazards assumption was checked and
confirmed for the significant covariates with log (log
[survival]) curves. Association of mortality with recurrent
stenosis, need for hemodialysis, and long-term clinical out-
comes was checked in separate univariate models with the
time-dependent covariate. Logistic regression models were
used for outcomes measured shortly after the procedure
(complications, short-term clinical benefits). The depen-
dence of each covariate on the outcome was first checked
separately with the 2 test. Covariates with a significance
level of P  .10 were included in the multivariate stepwise
analysis.
RESULTS
Patient population. One hundred forty-six patients
were identified (66 men, 80 women; mean age, 71  10
years [range, 44-89 years]). Comorbid conditions and ath-
erosclerotic risk factors were typical for a population with
symptomatic peripheral vascular disease (Table I). One
hundred eighty-three stenotic renal arteries present in 146
patients required intervention. Principal indications for in-
tervention were hypertension (86%), elevated creatinine
concentration (55%), and hypertension and elevated creat-
inine concentration (42%; Table I). No patients without
hypertension and antihypertensive medications received
treatment. Diagnostic imaging, used to define the stenosis
and the anatomic and functional findings in each kidney,
are reviewed in Tables II and III. There was significant
vascular disease in both kidneys in 45% of patients (Table
Table I. Patient characteristics and indications for
intervention
Characteristic n %
Total patients 146
Male 66 45
Female 80 55
Cardiac
Myocardial infarction 53 36
Congestive heart failure 44 30
Coronary artery disease 74 50
Hypertension 145 99
Diabetes mellitus
Insulin-dependent 19 13
Non-insulin-dependent 24 16
Transient ischemic attack or stroke 36 25
Chronic renal insufficiency 51 35
Chronic obstructive pulmonary disease 19 13
Coagulopathy 3 2
Hyperlipidemia 76 52
Smoking 69 47
Previous vascular surgery 43 29
Indications
Hypertension 126 86
Elevated creatinine concentration 80 55
Hypertension and elevated
creatinine concentration
62 42
Pulmonary edema 13 9
Shrinking kidney mass 3 2
Asymptomatic disease 5 3II). Specific data related to each intervention and subse-
quent procedures in solitary and bilateral diseased kidneys
are summarized in Table III. One hundred fifteen of 137
stented lesions were ostial (84%). Thirty two of 39 patients
(82%) with angiographically confirmed bilateral renal artery
stenosis (50%) received treatment to obtain maximal
therapeutic benefit (64 of 78 arteries). Renal artery occlu-
sion in patients with bilateral disease was confirmed in all 15
patients at angiography. In the remainder of patients the
contralateral kidney was not addressed, because the kidney
was nonfunctioning (n  1), the patient died before the
opposite side could be addressed, or the patient refused
therapy.
Immediate outcomes (<3 months). In 4 vessels
(2.2%) the lesion could not be crossed, and these were
deemed immediate intention-to-treat failures. Technical
success was achieved in 179 vessels (98%). Post-procedure
vessel diameter was 5.5  0.8 mm (range, 3-8 mm).
Thirty-three procedure-related complications occurred in
27 interventions (18%); 9 of these were related to the access
site (5%). These included 7 stent dislodgements, 7 bleeding
episodes, 5 groin hematomas, 4 acute renal artery dissec-
tions, 4 femoral or axillary pseudoaneurysms, 3 procedural
kidney perforations, 2 peripheral embolizations to the foot,
and 1 renal artery occlusion. Four patients required surgery
secondary to procedural complications (3 explorations be-
cause of subcapsular or retroperitoneal hematomas, 1 sur-
gical revascularization). These complications did not result
in the loss of any kidney. Female gender and elevated
pre-procedure diastolic blood pressure were associated with
increased morbidity (Table IV). Major morbidity was 4%.
One major adverse cardiac event occurred after the proce-
dure, resulting in a 30-day mortality and in-hospital mor-
tality of 0.7%. No deaths occurred within 90 days as a result
of renal artery injury.
Immediate clinical benefit for patients with hyperten-
sion and renal impairment within 3 months of the proce-
dure is summarized in Table V. Fifty-two percent of pa-
tients who received treatment of hypertension showed
immediate clinical benefit (improved or cured hyperten-
sion). In patients who received treatment of elevated serum
creatinine concentration (1.5 mg/dL), 87% showed sta-
bility of or decrease in serum creatinine concentration after
the procedure. Diastolic blood pressure was statistically
improved within 3 months after the procedure in patients
receiving treatment of hypertension, elevated creatinine
concentration, or both. Systolic blood pressure was statis-
tically improved within 3 months after the procedure in
patients receiving treatment of hypertension. Patients with
cerebrovascular disease and elevated pre-procedure systolic
blood pressure demonstrated immediate treatment success
for hypertension. Pre-procedure creatinine concentration
greater than 2.5 mg/dL was associated with deterioration
of creatinine concentration within 3 months of the proce-
dure (Table IV).
Outcomes (>3 months). Patient mortality for total,
hypertensive, and renal dysfunction population by life table
analysis was 25%, 21%, and 27% at 5 years (Fig). Nineteen
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lated, 6 were not cardiac related, and 5 were renal related.
Immediate and long-term creatinine concentration deteri-
oration and dialysis post-procedure were associated with
increased mortality. Elevated pre-procedure systolic blood
Table II. Preprocedural data
Bilateral vessel status
Stenosis (50%)  normal
Stenosis (50)  stenosis (50%)
Bilateral Stenosis (50%)
Stenosis (50%)  occlusion
Stenosis (50%)  absent
HTN
Ipsilateral kidney
Size (cm) 10.4  1.3
Resistive index 0.73  0.10
Contralateral kidney
Size (cm) 9.9  1.6*
Resistive index 0.74  0.13
Creatinine concentration (mg/dL) 1.7  1.2*
Creatinine clearance (mL/min) 48  27*
Systolic blood pressure (mm Hg) 181  28
Diastolic blood pressure (mm Hg) 90  17
Number of medications 3.0  1.0
HTN, Hypertension; Cr, creatinine concentration.
*P  .05.
Table III. Diagnostic, anatomic, and procedural data
n %
Procedures 183
Diagnostic imaging
Angiography 176 98
Duplex ultrasound scanning 47 26
Magnetic resonance angiography 32 18
Isotope scanning 30 17
Side
Left 100 55
Right 83 45
Number of renal vessels (mean  SD) 1.1  0.2
Number of lesions (mean  SD) 1.0  0.1
Degree of vessel stenosis (%) 80  10
Site of stenosis
Ostial 138 75
Proximal 39 21
Middle 6 3
Procedure
Angioplasty 46 25
Primary stent placement 125 68
Total stent placement 137 75
Contrast medium
Ionic 166 91
Gadolinium or carbon dioxide 17 9
Subsequent ipsilateral procedure 13 7.1
Bilateral kidney treatment 64* 35
Complications 33 18
*Sixty-four arteries in 32 patients.pressure was associated with lower mortality. Recurrent
stenosis and treatment failure for hypertension were not
associated with mortality (Table IV). When the population
was stratified by pre-procedure creatinine concentration, in
those with a creatinine concentration of 2.5 mg/dL or
greater the mortality rate was 38%, whereas in those with a
creatinine concentration less than 2.5 mg/dL the mortality
rate was 23%, at 5 years (P  .08). Analysis by creatinine
clearance was performed, and yielded similar results as with
serum creatinine concentration, and gave no additional
improvement in predictive ability.
The primary patency rate was 82%  9% at 5 years.
There were 17 endoluminal interventions in 13 patients to
treat recurrent stenosis. There was only one vessel occlu-
sion at 5.5 years. The 5-year rate of repeat intervention was
14%  6% (95% confidence interval [CI], 3%-25%), with a
median time of 0.7 years to this procedure. After repeat
interventions to treat recurrent stenosis the primary assisted
patency rate was 100% at 5 years (Fig). By multivariate
analysis, secondary interventions did not influence the pri-
mary end points of this study. The primary recurrent ste-
nosis rate was 30%  7% at 5 years, and the secondary
recurrent stenosis rate was 0% at 5 years. Five surgical
revascularization procedures to treat recurrent symptoms
with recurrent stenosis were required in 4 patients treated
percutaneously during follow-up of more than 5 years. No
factors were associated with the development of recurrent
stenosis.
Cumulative freedom from worsening hypertension was
89%  3%, 78%  6%, and 68%  9% at 1, 3, and 5 years,
respectively (Fig). Hyperlipidemia was associated with free-
dom from worsening hypertension. Cumulative freedom
from dialysis, renal disease–related mortality, or greater
No. of
patients %
68 47
12 8
39 27
15 10
12 8
Cr Total Range
10.2  1.2 10.3  1.2 7.0–13.7
0.75  0.10 0.73  0.10 0.32–0.89
9.2  1.6* 9.9  1.5 4.7–13.0
0.73  0.20 0.74  0.13 0.45–0.93
2.4  1.3* 1.8  1.2 0.6–9.1
33  20* 46  26 3–163
168  28 176  30 100–240
87  18 88  18 40–140
3.0  1.0 2.9  1.1 0.0–6.0
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concentration was 67% 5%, 50% 7%, and 45% 9% at
1, 3, and 5 years, respectively. When stratified by pre-
procedure serum creatinine concentration of less than or
greater than 2.5 mg/dL, this cumulative freedom was 39%
 8% (95% CI, 23%-55%) and 30%  12% (95% CI,
7%-53%) at 5 years, respectively (P .02). Analysis accord-
ing to creatinine clearance was performed, and yielded
similar results as those with serum creatinine concentration,
and gave no additional improvement in predictive ability.
In patients with creatinine concentration less than 1.5
mg/dL (n  66), 97% within 3 months and 72% within 5
years had a cumulative freedom from dialysis, renal disease–
related mortality, or greater than 20% elevation in post-
procedure serum creatinine concentration. Immediate
treatment success for creatinine was associated with in-
creased freedom from dialysis, renal disease–related mortal-
ity, or greater than 20% elevation in post-procedure serum
creatinine concentration (Table IV). Immediate treatment
success for hypertension and creatinine was associated with
reduced renal- related morbidity and mortality for all pa-
tients.
Twenty three patients ultimately were dialysis-depen-
dent within 3 years of their interventions (Table VI).
Twenty of 23 patients had patent or stenosed less than 50%
renal arteries at last follow-up with duplex ultrasound scan-
ning. The mean pre-procedural serum creatinine concen-
tration and creatinine clearance in the dialysis-dependent
group was significantly impaired compared with the non-
dialysis group. Thirteen patients showed worsening renal
Table IV. Proportional hazards and logistic regression mo
Patient characteristics
H
Associated with mortality*
Creatinine deterioration within 3 mo
Creatinine deterioration after 3 mo
Dialysis
Systolic blood pressure  140 mm Hg
Associated with morbidity*
Female gender
Diastolic blood pressure 90 mm Hg
Associated with immediate treatment failure
for hypertension*
Cerebrovascular disease
Systolic blood pressure 140 mm Hg
Associated with long-term treatment failure
for hypertension*
Hyperlipidemia
Associated with immediate treatment failure
for creatinine*
Preprocedure creatinine 2.5 mg/dL
Associated with long-term treatment failure
for creatinine*
Creatinine deterioration within 3 mo
Time to renal-related morbidity and
mortality*
Hypertension treatment failure within 3 mo
Creatinine treatment failure within 3 mo
*P  .05.function within 6 months after the procedure. Life table
analysis at 3 years showed 20% mortality in the dialysis
group and 9% mortality in the non-dialysis group (P 
.001). Three deaths (13%) were attributed to renal causes,
compared with non-dialysis renal mortality of 1.6%. Five
patients with a pre-procedure serum creatinine concentra-
tion less than 1.5 mg/dL receiving treatment of hyperten-
sion alone and with ostial lesions became dialysis-depen-
dent within 3 years of intervention. Three of these five
patients died (60% considered renal-related). Two of these
patients had immediate serum creatinine concentration
deterioration within 3 months of the procedure. Two of
these five patients (40%) required subsequent procedures
on the ipsilateral vessel. All treated vessels remained patent.
DISCUSSION
Mortality. Renal artery stenosis is an independent
predictor of mortality. At 7 years, 73% of patients with renal
artery stenosis are dead.13 The 5-year mortality in this study
was 25%, which is better than in patients with untreated
renal artery stenosis, comparable to that in patients treated
with surgical revascularization,14,15 and much better than
in other endoluminal studies.6-8 Immediate and long-term
post-procedure creatinine deterioration and dialysis depen-
dency were associated with increased mortality in this
study. Elevated creatinine concentration affects survival
after therapy for renal artery stenosis despite adequate
revascularization.5,7 Furthermore, increased survival may
be biased, on the basis of patient selection (ie, patients
suited for operative repair underwent endoluminal therapy,
rds
o Odds ratio
95% Confidence
interval
3 2.57–25.1
4 1.58–15.45
5 1.34–11.1
7 0.08–0.96
6.33 1.92–20.9
3.29 1.22–8.88
0.36 0.15–0.92
0.14 0.03–0.68
1 0.11–0.86
4.35 1.04–18.1
6 1.71–8.70
3 1.20–4.92
5.31–48.2dels
aza
rati
8.0
4.9
3.8
0.2
0.3
3.8
2.4
16.0
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artery disease did not affect survival), a demographically
mixed population with more women (compared with the
study by Yutan et al6), a healthier cohort of patients, and
patients lost to follow-up. Despite these factors, regardless
of treatment indication, short-term and long-term treat-
ment success for elevated creatinine positively affects
survival.
Anatomic outcome and patency. Technical success
of angioplasty or stenting at this institution is 98%. This
compares favorably with pooled data for angioplasty and
stenting that show a success rate of 82% to 100%.15 In
studies of angioplasty, success is higher for nonostial lesions
(72%-82%) than for ostial lesions (60%-62%). Ostial lesions
represent an extension of aortic atherosclerotic disease,
making them more difficult to treat.16 In this study, 75% of
arteries were stented, and 75% of lesions were considered
ostial; most stents (84%) were for ostial lesions. The use of
stents to correct ostial disease may explain the sustained
anatomic results.
Excellent primary patency and primary assisted patency
rates were also achieved at our institution (82% and 100% at
5 years), with only one vessel occlusion at 5.5 years. A
Table V. Immediate clinical response
Indication n
Deteriora
n
Hypertension 126 0
Elevated creatinine  1.5 mg/dL 80 10
Elevated Creatinine  2.5 mg/dL 20 5
Elevated creatinine 1.5–2.5 mg/dL 60 5
Indication Parameter n
All 146
SBP (mm Hg)
DBP (mm Hg)
No. of medications
Creatinine (mg/dL)
Hypertension 126
SBP (mm Hg)
DBP (mm Hg)
No. of medications
Creatinine (mg/dL)
Elevated creatinine 80
SBP (mm Hg)
DBP (mm Hg)
No. of medications
Creatinine (mg/dL)
Hypertension and
elevated
creatinine
62
SBP (mm Hg)
DBP (mm Hg)
No. of medications
Creatinine (mg/dL)
DBP, Diastolic blood pressure; SBP, systolic blood pressure.
*Number of patients and (percentages) of total treated patients for the resp
†Values are mean  SD.recent study of endoluminal stents placed to treat renal
artery stenosis demonstrated a primary patency rate of 77%
at an average of 18 months of follow-up.17 A comparison of
angioplasty and surgery shows primary recurrent stenosis–
free patency rates of 17% to 75% and 81% to 96%, respec-
tively, at 4 years.8,18 Comparison of our study results with
the natural history of medically managed renal artery ste-
nosis3,19,20 may suggest that percutaneous therapy is no
better than medical management, on the basis of patency
data. The natural rate of occlusion is 5% per year, and the
risk for occlusion is greater in vessels with higher stenoses.
A problem with natural history studies is that candidates
not considered for intervention were included, and there
was significant crossover of patients requiring intervention.
In addition, patients in whom the role of early renal revas-
cularization was uncertain were included. In our study,
patients had an average stenosis of 80%, that is, high-grade
stenoses more likely to occlude. Furthermore, the 18%
failed primary patency rate at 5 years represents vessels
treated for symptomatic recurrent stenosis, because there
were no occlusions within 5 years. Patency was improved
with secondary interventions to 100%, better than the
natural history of this disease. This emphasizes the need for
Response*
No effect improved cured
n % n % n %
61 48 49 39 16 13
60 75 9 11 1 1
13 65 2 10 0 0
47 78 7 12 1 2
Preprocedure† Postprocedure† P
176  30 161  25 .01
88  18 83  15 .01
2.9  1.0 2.8  1.2  .07
1.8  1.2 1.7  0.9  .87
181  28 159  23 .01
90  17 84  14 .01
3.0  1.0 2.8  1.2  .10
1.7  1.2 1.6  0.9  .39
168  29 157  25  .1
87  18 84  15  .03
3.1  1.0 2.8  1.2  .9
2.4  1.3 2.2  1.0  .5
171  27 155  24  .03
90  17 86  14  .01
3.1  1.0 2.8  1.3  .35
2.4  1.4 2.2  1.0  .42
subgroup.tion
%
0
13
25
8
ective
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Volume 39, Number 3 Sivamurthy et al 571Top, Life table analysis of the entire study population (black circles), patients with hypertension (gray circles), and patients with renal
dysfunction (triangles). Middle, Cumulative primary patency (gray circles), primary assisted patency (black circles), and primary recurrent
stenosis–free (triangles) intervals for all vessels. Bottom, Life table analysis of the likelihood of continued deterioration in blood pressure
(black circles) and renal function (gray circles) after renal angioplasty with or without stenting. The number of patients or vessels in each
interval is given in the table to the left of the corresponding graph. Values represent mean  SE 10% for all data points.
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minal procedures to maintain vessel patency after the pri-
mary intervention.
Recurrent stenosis for angioplasty of atherosclerotic
renal artery stenosis ranges from 10% to 47%, which is
attributed to the elastic recoil and rigidity of these lesions,
potential for arterial dissection, and inability to cope with
ostial plaque.15 The use of stents decreases the rate of
recurrent stenosis to 11% to 23% at 1 year, consistent with
our 5-year recurrent stenosis rate.15,21 No factors were
identified that contributed to recurrent stenosis, including
vessel size, placement of a stent, or the presence of cardio-
vascular risk factors. Although recurrent stenosis could be
adequately treated to maintain vessel patency, it did not
affect functional outcomes.
Functional outcome. Maintenance of clinical benefit
from percutaneous therapy for hypertension and renal dys-
function was mixed and not so effective as surgery.14 A
modest 52% of patients who received treatment of hyper-
tension had immediate improvement, and no patients were
made worse by the treatment. This result is slightly lower
than the 68% obtained by Yutan et al.6 Recent studies
suggest that the use of endoluminal therapy to cure hyper-
tension from atherosclerotic renal artery stenosis is
rare.7,9,21,22 Usually there is an improvement in blood
pressure and a reduction in the number of medications.22
Webster et al22 compared angioplasty with best medical
Table VI. Comparison of patients requiring or not requiri
Patient characteristics
Dia
n
Total 23
Male 7
Female 16
Indication
Hypertension alone 5
Elevated creatinine alone 2
Hypertension and elevated creatinine 16
Stent placement 20
Complications 2†
Hypertension alone 0
Elevated creatinine alone 0
Hypertension and elevated creatinine 2
Total mortality at 3 y 7
Renal-related mortality 3
Hypertension alone 2
Elevated creatinine alone 0
Hypertension and elevated creatinine 1
Patient characteristics Mean  S
Pre-procedure creatinine (mg/dL) 3.1  2.
Pre-procedure creatinine clearance (mL/min) 32  22
Freedom from dialysis, renal-related death, or
20% increase in creatinine (y)
0.9  1.
Duration of blood pressure benefit (y) 2.9  2.
Average follow-up (y) 2.7  2.
*Percent of total number of patients.
†Peripheral embolization and stent dislodgement to iliac arteries.therapy, and found no difference between treatments for
hypertension in unilateral disease. However, in bilateral
disease angioplasty can decrease blood pressure and reduce
the number of medications required. Results of this study
may be explained by the 82% of bilateral disease that was
treated. Furthermore, reduction in systolic and diastolic
blood pressure was statistically significant without a statis-
tically significant reduction in medications. However, it was
difficult to assess medications, because many medications
used in this patient population have dual indications. Blood
pressure response had no effect on follow-up cardiovascular
morbidity and patient mortality. Although systolic blood
pressure was statistically lowered with treatment, by itself it
may not have been enough to change the category of
response (Table V). However, immediate improvement of
hypertension from percutaneous therapy positively affected
renal function and freedom from renal-related mortality
(Table IV). Extended analysis of patients in this study
shows a modest number of patients maintained the clinical
improvement in hypertension. Steinbach et al23 and Yutan
et al6 reported long-term improvement of hypertension at
72% and 52%, respectively.
Functional outcome in patients with renal impairment
was not so promising. Creatinine concentration was stabi-
lized or decreased in 87% of patients in the first 3 months.
However, these improvements were not maintained during
extended follow-up (45% at 5 years). When stratified by
ialysis post-procedure
No dialysis
P% n %
15.8* 123 84.2*
30.4 59 48.0
69.6 64 52.0
21.7 59 48.0
8.7 18 14.6
69.6 46 37.4
117
8.7 31 25.2
18
1
6
20.0 12 9.0 .01
13 2 1.6
0
1
1
Range Mean  SD Range P
0.9–9.1 1.6  0.7 0.6–4.3 .01
3–82 49  26 9–164 .01
0–4 1.7  1.8 0–8 .01
0–6 1.9  1.9 0–8 .03
0–6.6 1.6  2.0 0–10 .01ng d
lysis
D
2
0
0
0
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creatinine concentration (2.5 mg/dL) had significantly
increased mortality and a poor rate of retained clinical
benefit. Even with such stratification, long- term functional
outcome was poor, with no subgroup demonstrating im-
provement. However, patients with immediate stabiliza-
tion or improvement in serum creatinine concentration had
a greater rate of freedom from dialysis and renal-related
mortality. When compared with surgery, the immediate
improvement in creatinine concentration (12%) and the
long-term maintenance are poor. These observations are
likely secondary to the definition of the outcome catego-
ries, the limitation of serum creatinine in determining poor
renal function, our standard for nonfunctioning kidneys,
limitations of the procedure, and patient selection. In 75%
of patients serum creatinine concentration stabilized imme-
diately after therapy. This category of patients needs to be
better defined and optimized, and includes patients who
may have had divergent outcomes over extended follow-
up. Although not specifically investigated in this study, the
category of renal dysfunction contributes to clinical out-
come after surgical revascularization.24 Thirty-six percent
of patients with chronic renal failure and 62% of patients
with rapidly declining renal function had improvement in
renal function after revascularization at 19-month follow-
up.25 We acknowledge the limitation in measuring serum
creatinine concentration to assess the early response to
treatment. In patients who had a modest preoperative
creatinine concentration of less than 2.0 mg/dL, early
improvements in the serum creatinine level were not evi-
dent despite measurable improvements in glomerular filtra-
tion rate.26 Serum creatinine concentration may not be the
best outcome measure to determine treatment response,
and may have been too late in identifying those patients
who had minimal end organ disease. With rising creatinine
concentration, renal function has declined significantly.
Revascularization before creatinine concentration rises and
parenchymal mass is lost may be a better approach.12 Late
outcomes with surgery and percutaneous therapy are better
when pre-procedure renal function is normal, as noted in
this study.12,23 No factors at duplex ultrasound scanning
predicted response to therapy in this study. Furthermore,
this study may have been more aggressive with “nonfunc-
tioning” kidneys, because some of the criteria used to
define nonfunctioning kidneys do not correlate with recov-
ery of function after open repair. Gill-Leertouwer et al24
suggests that in patients with renal impairment lateraliza-
tion to the affected kidney on a renal scintigram is a
predictor of clinical success. More “nonfunctioning” kid-
neys may have been treated with our criteria.
Limitations of the procedure include inability to treat
distal disease in the kidney, and atheroemboli. Of concern
in this study is that 23 patients (16%) became dialysis-
dependent after the procedure. Furthermore, this subset of
patients had a 20% mortality rate, compared with 9% in the
non-dialysis group, at 3 years. More disturbing is that five
patients who received treatment of hypertension alone,
with normal serum creatinine concentration, kidney size,resistive index, and creatinine clearance, became dialysis-
dependent. The increased number of patients requiring
dialysis post-procedure in this study emphasizes the risk
associated with endovascular renal revascularization and
the potential need for distal protection devices to improve
the outcome of endoluminal therapy for renal artery steno-
sis.27 Patient selection may have also contributed to the
results. Early in our experience we were more liberal in our
treatment, but have since become more conservative. A
negative selection bias from treating severe disease, ostial
disease, and bilateral disease may have influenced out-
comes. These functional results indicate that it is essential
to develop better criteria to identify those at risk for treat-
ment failure and better outcome measures of renal failure.
This study does not advocate the liberal use of catheter
intervention for renal artery stenosis. Despite the excellent
technical outcomes, this study points out the limitations of
intervention and the need for proper patient selection.
There was a higher complication rate than in other stud-
ies.5,6 Although most complications were minor, four pa-
tients required surgery to address them. Our technique
improved with experience and time. In addition, 16% of
patients became dialysis-dependent. It is unclear whether
these patients would have required dialysis without treat-
ment. However, the five patients with normal creatinine
concentration who became dialysis-dependent emphasize
the risk of this procedure. We may have been too aggressive
in our treatment protocol. Further assessment of functional
outcomes was not so promising. This study may have
underestimated the extent of renal disease and end organ
injury by using serum creatinine concentration, especially
in patients with stable renal function after the procedure.
Future studies should consider better criteria to determine
renal dysfunction and categorize outcomes. The goal
should be to treat only symptomatic renal artery stenosis
with objective evidence of reversible end organ disease.
Reviewing natural history data for renal artery stenosis,
progression to occlusion occurs at a modest rate, especially
with high-grade stenosis. Furthermore, patients who re-
ceived medical management had decreasing kidney size
over time, which emphasizes the need for invasive therapy.3
However, this study shows that all patients with symptom-
atic stenosis do not benefit from therapy. Medical manage-
ment may still be appropriate in a subset of patients.
In conclusion, this study shows that endoluminal inter-
vention to treat symptomatic atherosclerotic renal artery
stenosis is technically successful, with excellent anatomic
results. There are excellent patency and modest recurrent
stenosis, which can be treated with secondary interven-
tions. The number of patients unexpectedly requiring dial-
ysis after percutaneous therapy and the number of proce-
dural complications cautions against aggressive
prophylactic therapy. Despite these limitations, patients
with immediate treatment success were more likely to have
greater freedom from renal morbidity and mortality. In
summary, endovascular interventions may enhance the care
of the patient with hypertension, but does not appear to
preserve long- term renal function in the patient with
JOURNAL OF VASCULAR SURGERY
March 2004574 Sivamurthy et alchronic renal impairment. Further analysis and randomized
studies will be required to better define these disappointing
outcomes in chronic renal insufficiency and to determine
the appropriate time frame in which to pursue revascular-
ization.
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